drugset / Trial / NCT05204394
Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
Multicenter, open-label, randomized, active control study to evaluate efficacy and safety of switching to VM-1500A-LAI + 2NRTIs from the 1st line standard of care therapy for 48 weeks. The 1st part of the study will select one of 2 dose cohorts: 600mg or 900mg.
Timeline
- Start
- 2022-04-01
- Primary completion
- 2023-09-30
- Completion
- 2023-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elsulfavirine | Small molecule | 600 mg | Intramuscular |
| Subject | Elsulfavirine | Small molecule | 900 mg | Intramuscular |